@article{houot:hal-01903056,
TITLE = {Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma a phase II LYSA study},
AUTHOR = {Houot, Roch and Cartron, Guillaume and Bijou, Fontanet and de Guibert, Sophie and Salles, Gilles A and Fruchart, Christophe and Bouabdallah, Krimo and Maerevoet, Marie and Feugier, Pierre and Le Gouill, Steven and Tilly, Herv{\'e} and Casasnovas, Rene-Olivier and Molu{\c c}on-Chabrot, C{\'e}cile and van den Neste, Eric and Zachee, Pierre and Andre, Marc and Bonnet, Christophe and Haioun, Corinne and van Hoof, Achiel and van Eygen, Koen and Molina, Lysiane and Nicolas-Virelizier, Emmanuelle and Ruminy, Philippe and Morschhauser, Franck},
URL = {https://univ-rennes.hal.science/hal-01903056},
JOURNAL = {Leukemia},
PUBLISHER = {Springer Nature},
VOLUME = {33},
NUMBER = {3},
PAGES = {776-780},
YEAR = {2019},
MONTH = Mar, DOI = {10.1038/s41375-018-0282-y},
KEYWORDS = {Lenalidomide ; Mantle cell lymphoma ; Diffuse large B cell lymphoma ; Obinutuzumab},
PDF = {https://univ-rennes.hal.science/hal-01903056/file/Houot_Obinutuzumab%20plus%20Lenalidomide_revised%20manuscript_clean.pdf},
HAL_ID = {hal-01903056},
HAL_VERSION = {v1},
}